PMID: 17062685

Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6094-9., 2006-10-15 [PubMed]
Sentences
No. Mutations Sentence Comment
11 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 17062685:11:194
status: VERIFIED
view ABCG2 p.Gln141Lys details
 Conclusions: DV and DE doublets are active with a tolerable toxicity profile in patients with HRPC; however, efficacy does not seem superior to standard single-agent docetaxel.The ABCG2 421C>A (Q141K) polymorphism may be an important predictor of response and survival in HRPC patients treated with docetaxel-based chemotherapy. Login to comment 121 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 17062685:121:88
status: VERIFIED
view ABCG2 p.Gln141Lys details
 In this pilot analysis, it was noted that 4 of 6 (66%) patients with the ABCG2 421 C>A (Q141K) polymorphism were alive past 15 months compared with only 12 of 44 (27%) patients with wild-type (C/C; P = 0.05). Login to comment